Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
These medicines are essential in preventing RhD immunisation during pregnancy
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
The facility will manufacture 13,200 MTPA Benzyl Chloride, 9,600 MTPA Benzyl Alcohol, and 7,200 MTPA Benzaldehyde
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
Surpassing 1,000 Company Owned Company Operated stores
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
Subscribe To Our Newsletter & Stay Updated
